ArticleFujita medical journal2025
Investigation of prognostic factors in patients with terminal pancreatic cancer: Focus on clinical symptoms, cachexia-related proteins, and body composition analysis at admission.
Article in Fujita medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of the prognostic nutritional index for patients with renal cell carcinoma: an update systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Therapeutic effects of pleural and abdominal fluid filtration, concentration, and reinjection based on bioelectrical impedance analysis.Fujita medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In palliative medicine, accurate prognosis of patients with terminal cancer is crucial. Serum albumin (Alb), transthyretin (TTR), and C-reactive protein (CRP) have been reported to be associated with prognosis. Pancreatic cancer is generally a rapidly progressing disease with an extremely poor prognosis. In the present study, we focused on identifying prognostic factors in patients with terminal pancreatic cancer. Methods: Overall, 756 patients with terminal cancer were admitted for palliative care and died during the 3-year period from April 2018; of these, 72 patients with pancreatic cancer (9.5%; excluding those who died within 7 days of admission) were included in the study. In addition to assessing clinical symptoms at admission, blood tests were performed to measure serum Alb (g/dL), TTR (mg/dL), CRP (mg/dL), and tumor markers. Body composition was analyzed using bioelectrical impedance analysis (BIA; InBody S10) to determine skeletal muscle mass index (SMI, kg/m Results: The median age was 75 years (range: 33-91 years), with a male-to-female ratio of 37:35. The median survival time was 24 days (range: 7-99 days). After adjusting for age, sex, and performance status as potential confounders, multivariate analysis revealed that CRP (hazard ratio [HR]: 1.0998; 95% confidence interval [CI]: 1.0248-1.1781; Conclusion: Patients with terminal pancreatic cancer presented with advanced chronic inflammation at admission in addition to cachexia. Multivariate analysis revealed that serum CRP level and ECW/TBW ratio are independent prognostic factors, suggesting that prognosis in terminal pancreatic cancer is associated with the severity of chronic inflammation and edema. Among clinical symptoms, the degree of depression may also be related to prognosis, indicating that psychological distress should be considered in palliative care assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.